Cytokinetics Probability Of Bankruptcy

CYTK -  USA Stock  

USD 47.25  0.22  0.46%

Cytokinetics Probability Of Bankruptcy is used to show its chance of financial distress over the next two years of operations under current economic and market conditions. Cytokinetics Probability Of Bankruptcy is determined by interpolating and adjusting Cytokinetics Altman Z Score to account for off-balance-sheet items and missing or unfiled public information. All items used in analyzing the odds of distress are taken from the Cytokinetics balance sheet as well as cash flow and income statements available from the company's most recent filings. Continue to Cytokinetics Piotroski F Score and Cytokinetics Altman Z Score analysis.
  
Refresh
Cytokinetics Invested Capital Average is increasing as compared to previous years. The last year's value of Invested Capital Average was reported at 814.76 Million. The current Market Capitalization is estimated to increase to about 4.1 B, while Earnings Before Interest Taxes and Depreciation Amortization EBITDA are projected to decrease to (201.8 M).

Cytokinetics Probability Of Bankruptcy Analysis

Cytokinetics' Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.
Probability Of Bankruptcy 
 = 
Normalized 
 
Z-Score 
More About Probability Of Bankruptcy | All Equity Analysis

Current Cytokinetics Probability Of Bankruptcy

    
  67%  
Most of Cytokinetics' fundamental indicators, such as Probability Of Bankruptcy, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Cytokinetics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Our calculation of Cytokinetics probability of bankruptcy is based on Altman Z-Score and Piotroski F-Score, but not limited to these measures. To be applied to a broader range of industries and markets, we use several other techniques to enhance the accuracy of predicting Cytokinetics odds of financial distress. These include financial statement analysis, different types of price predictions, earning estimates, analysis consensus, and basic intrinsic valuation. Please use the options below to get a better understanding of different measures that drive the calculation of Cytokinetics financial health.
Is Cytokinetics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cytokinetics. If investors know Cytokinetics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cytokinetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
3.7 B
Quarterly Revenue Growth YOY
-0.82
Return On Assets
-0.19
Return On Equity
-2.8
The market value of Cytokinetics is measured differently than its book value, which is the value of Cytokinetics that is recorded on the company's balance sheet. Investors also form their own opinion of Cytokinetics' value that differs from its market value or its book value, called intrinsic value, which is Cytokinetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cytokinetics' market value can be influenced by many factors that don't directly affect Cytokinetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cytokinetics' value and its price as these two are different measures arrived at by different means. Investors typically determine Cytokinetics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cytokinetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Cytokinetics Probability Of Bankruptcy Driver Correlations

Understanding the fundamental principles of building solid financial models for Cytokinetics is extremely important. It helps to project a fair market value of Ford stock properly, considering its historical fundamentals such as Probability Of Bankruptcy. Since Cytokinetics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Cytokinetics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Cytokinetics' interrelated accounts and indicators.
The Probability of Bankruptcy SHOULD NOT be confused with the actual chance of a company to file for chapter 7, 11, 12, or 13 bankruptcy protection. Macroaxis simply defines Financial Distress as an operational condition where a company is having difficulty meeting its current financial obligations towards its creditors or delivering on the expectations of its investors. Macroaxis derives these conditions daily from both public financial statements as well as analysis of stock prices reacting to market conditions or economic downturns, including short-term and long-term historical volatility. Other factors taken into account include analysis of liquidity, revenue patterns, R&D expenses, and commitments, as well as public headlines and social sentiment.
Compare to competition

Based on the latest financial disclosure, Cytokinetics has a Probability Of Bankruptcy of 67%. This is 54.77% higher than that of the Healthcare sector and 22.17% higher than that of the Biotechnology industry. The probability of bankruptcy for all United States stocks is 68.21% lower than that of the firm.
Chance Of Financial Distress
Over 67
Cytokinetics has more than 67 (%) percent chance of experiencing financial distress in the next two years of operations. The calculation of odds of distress for Cytokinetics stock is tightly coupled with the Probability of Bankruptcy. It complements the equity performance score by supplying investors with insight into company financials without requiring them to know too much about all of the complex accounting and financial indicators surrounding the entity. More Info

Cytokinetics Main Bankruptcy Drivers

201720182019202020212022 (projected)
Return on Average Assets0.12(0.42)(0.44)(0.56)(0.34)(0.31)
Asset Turnover0.250.780.0440.130.120.15
Total Debt31.78 M43.18 M136.07 M138.94 M269.93 M291.24 M
Total Liabilities184.97 M185.24 M300.75 M420.42 M597.46 M644.62 M
Current Liabilities32.44 M22.19 M26.02 M31.2 M71.86 M77.53 M
Total Assets294.81 M211.18 M289.81 M533.8 M841.32 M907.74 M
Current Assets274.3 M207.67 M233.75 M474.22 M535.67 M577.96 M
Net Cash Flow from Operations(101.76 M)(101.22 M)(90.91 M)8.94 M(142.52 M)(146.27 M)
Weighted Average Shares49.4 M54.42 M57.58 M64.52 M76.89 M65.44 M
Weighted Average Shares Diluted49.4 M54.42 M57.58 M64.52 M76.89 M65.58 M

Cytokinetics Fundamentals

About Cytokinetics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Cytokinetics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cytokinetics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cytokinetics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company was incorporated in 1997 and is headquartered in South San Francisco, California. Cytokinetics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 253 people.

Cytokinetics Investors Sentiment

The influence of Cytokinetics' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Cytokinetics. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock markets does not have a solid backing from leading economists and market statisticians.

Cytokinetics Implied Volatility

    
  74.3  
Cytokinetics' implied volatility exposes the market's sentiment of Cytokinetics stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Cytokinetics' implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Cytokinetics stock will not fluctuate a lot when Cytokinetics' options are near their expiration.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Cytokinetics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Cytokinetics' short interest history, or implied volatility extrapolated from Cytokinetics options trading.

Current Sentiment - CYTK

Cytokinetics Investor Sentiment

Most of Macroaxis users are currently bullish on Cytokinetics. What is your opinion about investing in Cytokinetics? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish

Pair Trading with Cytokinetics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cytokinetics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cytokinetics will appreciate offsetting losses from the drop in the long position's value.

Cytokinetics Pair Correlation

Correlation Analysis For Direct Indexing and Tax-loss Harvesting

The ability to find closely correlated positions to Cytokinetics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cytokinetics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cytokinetics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cytokinetics to buy it.
The correlation of Cytokinetics is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cytokinetics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cytokinetics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Cytokinetics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Continue to Cytokinetics Piotroski F Score and Cytokinetics Altman Z Score analysis. Note that the Cytokinetics information on this page should be used as a complementary analysis to other Cytokinetics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Commodity Channel Index module to use Commodity Channel Index to analyze current equity momentum.

Complementary Tools for Cytokinetics Stock analysis

When running Cytokinetics price analysis, check to measure Cytokinetics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cytokinetics is operating at the current time. Most of Cytokinetics' value examination focuses on studying past and present price action to predict the probability of Cytokinetics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Cytokinetics' price. Additionally, you may evaluate how the addition of Cytokinetics to your portfolios can decrease your overall portfolio volatility.
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Go
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Go
Price Transformation
Use Price Transformation models to analyze depth of different equity instruments across global markets
Go
CEO Directory
Screen CEOs from public companies around the world
Go
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Go
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Go
Equity Valuation
Check real value of public entities based on technical and fundamental data
Go
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Go
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Go
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Go
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Go
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Go
Is Cytokinetics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cytokinetics. If investors know Cytokinetics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cytokinetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
3.7 B
Quarterly Revenue Growth YOY
-0.82
Return On Assets
-0.19
Return On Equity
-2.8
The market value of Cytokinetics is measured differently than its book value, which is the value of Cytokinetics that is recorded on the company's balance sheet. Investors also form their own opinion of Cytokinetics' value that differs from its market value or its book value, called intrinsic value, which is Cytokinetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cytokinetics' market value can be influenced by many factors that don't directly affect Cytokinetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cytokinetics' value and its price as these two are different measures arrived at by different means. Investors typically determine Cytokinetics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cytokinetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.